INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,334,112 | -19.9% | 1,270,027 | +6.3% | 2.11% | +4.7% |
| Q2 2023 | $6,656,301 | -13.5% | 1,195,027 | -11.0% | 2.02% | -1.1% |
| Q1 2023 | $7,690,754 | +232.2% | 1,342,191 | -39.1% | 2.04% | +231.0% |
| Q4 2022 | $2,315,120 | -56.7% | 2,204,876 | +10.4% | 0.62% | -57.1% |
| Q3 2022 | $5,350,000 | -44.9% | 1,996,277 | -1.8% | 1.44% | -61.2% |
| Q2 2022 | $9,701,000 | +165.9% | 2,033,802 | +128.0% | 3.70% | +138.7% |
| Q1 2022 | $3,649,000 | -40.0% | 892,057 | 0.0% | 1.55% | -23.1% |
| Q4 2021 | $6,084,000 | -43.0% | 892,057 | -3.1% | 2.02% | -35.1% |
| Q3 2021 | $10,666,000 | -32.5% | 920,264 | -0.8% | 3.11% | -15.3% |
| Q2 2021 | $15,801,000 | -13.9% | 927,264 | 0.0% | 3.68% | 0.0% |
| Q1 2021 | $18,360,000 | -10.6% | 927,264 | -6.8% | 3.68% | -36.5% |
| Q4 2020 | $20,545,000 | -22.6% | 995,396 | -1.4% | 5.79% | -38.7% |
| Q3 2020 | $26,529,000 | – | 1,009,117 | – | 9.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |